Optimization of cultivation strategies for production of recombinant human papillomavirus type 58 major capsid protein L1 in Hansenula polymorpha

Abstract

Human papillomaviruses (HPVs) are a major cause of cervical cancer, which ranks fourth among cancers in women worldwide. A prophylactic vaccine composed of virus-like particles (VLPs) formed by the major capsid protein L1 of human papillomavirus (HPV) effectively prevents HPV infection but provides limited cross-protection against other HPV subtypes, highlighting the importance of multivalent prophylactic vaccines. In this study, cultivation conditions for recombinant HPV58 L1 protein production in the yeast Hansenula polymorpha were optimized to enhance growth and the volumetric yield of L1 protein. The results indicated that induction with methanol (at 1% v/v) was necessary for HPV58 L1 production in SYN6 medium, whereas a cultivation temperature of 37 °C was optimal for growth and production of HPV58 L1 protein. Subsequently, SYN6 medium supplemented with 10 g/L of either Hy-Express™ System II or HySoy was evaluated in batch and fed-batch bioreactor cultivations. Fed-batch cultivation with HySoy supplementation under a constant feeding rate achieved an OD₆₆₀ of 117 (26.18 g-CDW/L), a volumetric L1 yield of 312 mg/L, and a productivity of 4.7 mg/L/h, which were significantly higher than those obtained with the control SYN6 medium (92 mg/L; 2.2 mg/L/h). These findings demonstrate that fed-batch cultivation with HySoy supplementation offers a practical and efficient strategy for HPV58 L1 production at the bioreactor scale.

Graphical abstract

Keywords

HPV58 L1 / Hansenula polymorpha / Virus-like particles / VLP / Bioreactor

References

[1] Askwith C, Eide D, Van Ho A, et al.. The FET3 gene of S. cerevisiae encodes a multicopper oxidase required for ferrous iron uptake. Cell, 1994, 76: 403-410.

[2] Bogdanova AI, Agaphonov MO, Ter-Avanesyan MD. Plasmid reorganization during integrative transformation in Hansenula polymorpha. Yeast, 1995, 11: 343-353.

[3] Boontawon T, Thitithanyanont A, Boonchird C (2015) Construction of recombinant Hansenula polymorpha for expression of the codon-optimized major capsid protein L1 of human papillomavirus genotype 52 of proceedings. Proceedings in the Thai Society for Biotechnology and International Conference 2015 (TSB2015). Mandarin Hotel, Bangkok, Thailand, November. 17–21

[4] Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 1976, 72: 248-254.

[5] Bruni L, Albero G, Serrano B et al (2023) Human Papillomavirus and Related Diseases in the World. Summary Report 10 March 2023. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). https://hpvcentre.net/statistics/reports/XWX.pdf Accessed Date 03 Aug 2025

[6] Buck CB, Day PM, Trus BL. The papillomavirus major capsid protein L1. Virol, 2013, 445: 169-174.

[7] Chan PKS, Ho WCS, Chan MCW, Wong MCS, Yeung ACM, Chor JSY, et al.. Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide. PLoS ONE, 2014, 9(9): e107573.

[8] ClinicalTrials.gov. A phase III clinical trial of a 11-valent recombinant human papillomavirus vaccine (Hansenula polymorpha) in Chinese women aged 9–45 years (2025) https://clinicaltrials.gov/ct2/show/NCT05262010. Accessed 9 Mar 2026

[9] Degelmann A (2002) Methods. In G. Gellissen (ed) Hansenula polymorpha: Biology and Applications. Wiley-vch Weinheim 285–329. https://onlinelibrary.wiley.com/doi/https://doi.org/10.1002/3527602356.ch17

[10] Gaensly F, Picheth G, Brand D, et al.. The uptake of different iron salts by the yeast Saccharomyces cerevisiae. Braz J Microbiol, 2014, 45: 491-494.

[11] Gatzke R, Weydemann U, Janowicz Z, et al.. Stable multicopy integration of vector sequences in Hansenula polymorpha. Appl Microbiol Biotechnol, 1995, 43: 844-849.

[12] Gu S, Yang T, Shao Z et al (2020) Siderophore-mediated interactions determine the disease suppressiveness of microbial consortia. Msystems 5. https://doi.org/10.1128/msystems.00811-19. 10.1128/msystems. 00811 – 19

[13] Han S, Lin M, Liu M, Wu S, Guo P, Guo J, et al.. Prevalence, trends, and geographic distribution of human papillomavirus infection in Chinese women: a summative analysis of 2,728,321 cases. BMC Med, 2025, 23(1): 158.

[14] Hassett RF, Romeo AM, Kosman DJ. Regulation of high affinity iron uptake in the yeast : role of dioxygen and Fe (II). J Biol Chem, 1998, 273: 7628-7636.

[15] HDmall (2025) HPV vaccination. Thailand. Accessed Date 30 October 2025 https://hdmall.co.th/c/hpv-vaccine-price

[16] ICO/IARC Information Centre on HPV and Cancer. Thailand: human papillomavirus and related cancers, fact sheet 2023 (2023) https://hpvcentre.net/statistics/reports/THA_FS.pdf. Accessed 9 Mar 2026

[17] Jenzelewski V (2002) Fermentation and Primary Product Recovery. In G. Gellissen (ed) Hansenula polymorpha: Biology and Applications. Wiley-VCH Weinheim 156–174. https://doi.org/10.1002/3527602356.ch11

[18] Joura E, Pils S. Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?. Clin Microbiol Infect, 2016, 22: S125-S127.

[19] Kang HA, Gellissen G (2005) Hansenula polymorpha. In G. Gellissen (ed) Production of Recombinant Proteins: Novel Microbial and Eukaryotic Expression Systems. Wiley-VCH Weinheim 111–142. https://onlinelibrary.wiley.com/doi/epdf/https://doi.org/10.1002/3527603670.ch6

[20] Kirnbauer R, Booy F, Cheng N, et al.. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. PNAS, 1992, 89: 12180-12184.

[21] Kopitak N, Phathano P, Pongtharangkul T, Boonchird C, Charoenrat T, Theeranan T (2025) Optimizing primary isolation of recombinant HPV L1 protein type 58 from Hansenula polymorpha. Curr Appl Sci Technol e0265704. https://doi.org/10.55003/cast.2025.265704

[22] Lesuisse E, Raguzzi F, Crichton R. Iron uptake by the yeast Saccharomyces cerevisiae: involvement of a reduction step. J Gen Microbiol, 1987, 133: 3229-3236.

[23] Liu C, Yao Y, Yang X, et al.. Production of recombinant human papillomavirus type 52 L1 protein in Hansenula polymorpha formed virus-like particles. J Microbiol Biotechnol, 2015, 25: 936-940.

[24] Manfrão-Netto JHC, Gomes AMV, Parachin NS. Advances in using Hansenula polymorpha as chassis for recombinant protein production. Front Bioeng Biotechnol, 2019, 7: 94.

[25] Mayer AF, Hellmuth K, Schlieker H, Looser V, Veit I, Wenzel KW, Gellissen G (1999). An expression system matures: A highly efficient and cost-effective process for phytase production by recombinant strainsof Hansenula polymorpha. Biotechnology and Bioengineering, 63(3), 373–381. https://doi.org/10.1002/(SICI)1097-0290(19990805)63:3

[26] Mueller F, Moussa M, El Ghazaly M, et al.. Efficient production of recombinant parathyroid hormone (rPTH) fragment 1–34 in the methylotrophic yeast Hansenula polymorpha. GaBI J, 2013, 2: 114-122.

[27] Muñoz N, Bosch FX, De Sanjosé S, et al.. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 2003, 348: 518-527.

[28] National Vaccine and Serum Institute. A phase III clinical trial of a 11-valent recombinant human papillomavirus vaccine (Hansenula polymorpha) in Chinese women aged 9–45 years (2025) https://clinicaltrials.gov/ct2/show/NCT04436133. Accessed 10 Mar 2026

[29] National Vaccine and Serum Institute. Immunogenicity and safety study of the 11-valent recombinant human papillomavirus vaccine (Hansenula polymorpha) (2025) https://clinicaltrials.gov/ct2/show/NCT05262010. Accessed 10 Mar 2026

[30] Paronetto MP, Miele R, Maugliani A, et al.. Cloning of Pichia pastoris Fet3: insights into the high affinity iron uptake system. Arch Biochem Biophys, 2001, 392: 162-167.

[31] Petrosky E, Bocchini JAJr, Hariri S, et al.. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR, 2015, 64: 300-304

[32] Phimsen W, Kopitak N, Boontawon T, et al.. Optimizing the production of recombinant human papilloma virus type 52 major capsid protein L1 in Hansenula polymorpha. Sci Rep, 2024, 14: 28555.

[33] Ramos-Alonso L, Romero AM, Martínez-Pastor MT, et al.. Iron regulatory mechanisms in Saccharomyces cerevisiae. Front Microbiol, 2020, 11: 582830.

[34] Roggenkamp R, Hansen H, Eckart M, et al.. Transformation of the methylotrophic yeast Hansenula polymorpha by autonomous replication and integration vectors. Mol Gen Genet, 1986, 202: 302-308.

[35] Shemesh P, Fishman A. Optimal fermentation conditions for growth and recombinant protein production in pichia pastoris: strain selection, ploidy level and carbon source. Curr Res Food Sci, 2024, 9: 100840.

[36] Shen S, Guo S, Yao X, Wu Y, Xiang S, Meng Q. Epidemiological analysis of human papillomavirus and its subtype infections in 36248 women in Wuhan, China. Front Public Health, 2026, 14: 1745604.

[37] Stanford FA, Voigt K. Iron assimilation during emerging infections caused by opportunistic fungi with emphasis on Mucorales and the development of antifungal resistance. Genes, 2020, 11: 1296.

[38] Stöckmann C, Scheidle M, Dittrich B, et al.. Process development in Hansenula polymorpha and Arxula adeninivorans, a re-assessment. Microb Cell Factories, 2009, 8: 22.

[39] Suppi S, Michelson T, Viigand K, et al.. Repression vs. activation of MOX, FMD, MPP1 and MAL1 promoters by sugars in Hansenula polymorpha: the outcome depends on cell’s ability to phosphorylate sugar. FEMS Yeast Res, 2013, 13: 219-232.

[40] van Zutphen T, Baerends RJS, Susanna KA, de Jong A, Kuipers OP, Veenhuis M, van der Klei IJ. Adaptation of Hansenula polymorphato methanol: a transcriptome analysis. BMC Genomics. 2010;11:1. https://doi.org/10.1186/1471-2164-11-1

[41] Vogl T, Glieder A. Regulation of Pichia pastoris promoters and its consequences for protein production. N Biotechnol, 2013, 30: 385-404.

[42] Wang W, Chi Z, Chi Z, et al.. Siderophore production by the marine-derived Aureobasidium pullulans and its antimicrobial activity. Bioresour Technol, 2009, 100: 2639-2641.

[43] Wang R, et al.. Distribution of HPV types among women with HPV-related diseases and exploration of lineages and variants of HPV 52 and 58 among HPV-infected patients in China: a systematic literature review. Hum Vaccin Immunother, 2024, 20(1): 2345678.

[44] Wang R, et al.. Current status and future directions for the development of human papillomavirus vaccines. Vaccines, 2024, 12(7): 755.

[45] World Health Organization. Eradicating cervical cancer in Thailand: a journey of hope and progress. Bangkok: WHO Country Office for Thailand (2025) https://iris.who.int/handle/10665/382150. Accessed 9 Mar 2026

[46] Xia N, et al.. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomized, blinded, phase 3 trial. Lancet Infect Dis, 2025.

[47] Xu X, Ren S, Chen X, et al.. Generation of hepatitis B virus PreS2-S antigen in Hansenula polymorpha. Virol Sin, 2014, 29: 403-409.

[48] Yuan S, et al.. Immunogenicity assessment of a 14-valent human papillomavirus vaccine candidate in mice. Vaccines, 2024, 12(10): 1159.

Funding

Mahidol University

RIGHTS & PERMISSIONS

The Author(s)